Understanding Chemobrain and Its Potential Treatments
Written on
Chapter 1: Overview of Cancer and Chemotherapy
Cancer remains the second leading cause of mortality globally, with about 40% of individuals facing some form of it during their lifetime. This disease originates when a cell starts to replicate uncontrollably, disregarding the typical growth regulations. The driving force behind this abnormal behavior is often a series of genetic mutations. While not all mutations are detrimental, many can contribute to cancerous growth.
Mutations may arise from intrinsic factors; during cell division, DNA replication is generally precise but not infallible. Errors can accumulate, leading to cellular changes that promote cancer. External factors, such as overexposure to UV radiation, can also increase the risk of certain cancers like skin cancer. Additionally, pollutants and processed foods have been linked to lung and colorectal cancers, respectively. The gut microbiome plays a crucial role in cancer susceptibility and might even be harnessed to improve chemotherapy outcomes.
Age is a significant risk factor for most cancers, as more extended exposure to potential carcinogens and increased cell divisions lead to a higher likelihood of mutations. Moreover, older blood may contain substances that facilitate cancer spread once established. Recent research highlights the role of epigenetic modifications—chemical changes that can alter gene expression—in cancer progression. While numerous innovative treatments are being developed, chemotherapy remains the cornerstone of cancer care, often combined with surgery and/or radiation therapy. This approach, while life-saving, is somewhat blunt, relying on cytotoxic drugs to eliminate cancerous cells.
Chemobrain and Its Impact
The harshness of chemotherapy can lead to various side effects, including immune suppression, nausea, anemia, and hair loss. One significant concern is chemobrain, a term used to describe post-chemotherapy cognitive impairment. This phenomenon, supported mostly by patient anecdotes, has only recently gained wider recognition in the medical community.
Approximately 20–30% of chemotherapy recipients report experiencing cognitive fog post-treatment. Symptoms can include difficulty concentrating, impaired short-term memory, and struggles with word retrieval. While many patients may experience these symptoms during treatment, those with chemobrain often find them persisting long after their chemotherapy sessions have ended.
The underlying mechanisms of chemobrain are not yet fully understood. Potential explanations include direct damage to brain cells from chemotherapy agents, hormonal changes, vascular damage, oxidative stress, inflammation, and autoimmune responses. Interestingly, the APOE4 gene, which increases the risk for Alzheimer’s disease, may also influence the likelihood of developing chemobrain.
The following video from Dana-Farber Cancer Institute discusses "Chemo brain after cancer treatment," shedding light on this cognitive issue and its implications.
Preventing and Treating Chemobrain
Recent research involving female mice suggests that cognitive impairments caused by the chemotherapy drug paclitaxel could be alleviated with lithium and PKC inhibitors. Previous studies demonstrated that paclitaxel can cross the blood-brain barrier and induce peripheral neuropathy through InsP3R-dependent calcium oscillations—an essential process in cell signaling. Lithium pretreatment was shown to prevent this neuropathy.
Researchers posed several critical questions: Does paclitaxel also lead to chemobrain? If so, does it operate through similar mechanisms? Can these findings lead to treatment options?
The first question received a partial affirmative answer, as mice subjected to four injections of paclitaxel displayed diminished scores on a memory test without any noticeable changes in movement or anxiety.
Regarding the second question, the findings suggest that paclitaxel reduces the complexity of neurons in the hippocampus and cortex, leading to fewer connections between brain cells. They also observed an increase in PKC?, a vital component of the InsP3R pathway, indicating a link between neuropathy and cognitive impairment.
The answer to the third question appears positive; mice that received lithium before paclitaxel exhibited no memory deficits in the recognition test at both short (4-5 days) and long (22-23 days) intervals after chemotherapy. Another group treated with chelerythrine, a PKC inhibitor, also showed resilience against memory issues and changes in brain cell structure.
In conclusion, the study suggests a pathway for cognitive impairment induced by paclitaxel, indicating that lithium and PKC inhibitors may serve as effective preventive and therapeutic measures for chemobrain in cancer survivors.
Caveats to Consider
It is important to note that findings from animal studies do not always translate to human applications. The mice used in this research were healthy females, unlike the often compromised health of cancer patients undergoing chemotherapy. Moreover, only one aspect of memory was assessed, and only one chemotherapy agent was tested. While lithium is primarily used to treat psychological disorders, it can have side effects and requires careful dosage adjustments. Similarly, chelerythrine is being explored for its potential as an anti-cancer and antibacterial agent, but most studies have been conducted in animal models or cell lines, and it may inadvertently harm healthy cells.
The second video titled "Chemo Brain: Strategies for Improving Brain Fog (2023)" offers practical strategies to manage cognitive fog following chemotherapy, providing valuable insights for survivors.
Stay sharp.